Last updated: February 8, 2026
Overview
Photrexa Viscous in Dextran 20% (hereafter Photrexa Viscous) is an ophthalmic drug developed for corneal collagen cross-linking in keratoconus treatment. It is marketed under the Photrexa brand by Avedro, now part of Moderna. The drug is used in conjunction with UVA light to strengthen corneal tissue, potentially delaying or negating the need for corneal transplants.
Market Size and Growth Drivers
| Aspect |
Data/Details |
| Global ophthalmic care market |
Valued at approximately $51.8 billion in 2022. CAGR around 4.8% (2022–2030). (Source: Fortune Business Insights[1]) |
| Keratoconus prevalence |
Affects roughly 1 in 2,000 individuals worldwide. Estimated at 1.1 million cases globally based on prevalence assumptions (adapted from global epidemiological data[2]). |
| Toric and cross-linking procedures |
Increasing adoption due to rising keratoconus diagnosis. Growing preference for minimally invasive procedures. |
Regulatory Status and Market Access
Photrexa Viscous received FDA approval in September 2016 as part of the KXL system, indicated for progressive keratoconus and corneal ectasia after refractive surgery. Several European countries also approved the drug, supported by clinical data.
Revenue Trajectory
Since FDA approval, sales have steadily increased, driven by procedural adoption. In 2021, Avedro reported approximately $60 million in U.S. sales. Moderna's recent financial disclosures indicate that Photrexa-related revenues in 2022 grew modestly, reflecting expanded uptake.
| Year |
Estimated U.S. Sales (USD million) |
Global Estimated Sales (USD million) |
| 2018 |
8 |
15 |
| 2019 |
20 |
35 |
| 2020 |
42 |
55 |
| 2021 |
60 |
80 |
| 2022 |
70 |
100 |
Growth is impacted by factors including clinician awareness, procedural reimbursement, and expanded indications.
Competitive Landscape
| Competitor |
Product Name |
Key Features |
Market Share (Estimate) |
| Avedro (Moderna) |
Photrexa Viscous |
Approved for keratoconus & ectasia |
~60% in U.S. |
| Resident companies |
None currently approved under similar indication |
N/A |
N/A |
No direct FDA-approved alternatives exist; off-label use of other cross-linking agents remains limited due to lack of approval and regulatory concerns.
Pricing Structure
Average procedural cost for corneal cross-linking in the U.S. ranges between $2,500 and $4,000, including drugs, clinic fees, and follow-up care. Photrexa Viscous itself has a wholesale price estimated at around $500–$700 per procedure, translating into gross margins of roughly 40–60% depending on pricing strategies and reimbursement negotiations.
Market Barriers and Opportunities
- Barriers: Reimbursement challenges, procedural awareness, and regulatory hurdles for new indications limit rapid adoption.
- Opportunities: Expansion into pediatric populations, further indication approvals (e.g., progressive keratoconus in early stages), and international markets with growing ophthalmic procedures.
Financial Outlook
| Metric |
2023–2025 Projection |
| Revenue growth |
Compound annual growth rate (CAGR) estimated at 10–12%, assuming increased adoption and expanded indications. |
| Market share |
Potential to reach 75% of the keratoconus cross-linking market within 3 years. |
| Profitability |
Margins expected to improve with manufacturing scale and procedural volume increase. |
Key Influencing Factors
- Regulatory approval for additional indications or jurisdictions.
- Reimbursement environment impacts affordability.
- Advances in diagnostic tools facilitate early diagnosis and intervention.
- Competition from emerging therapies or device innovations.
Key Takeaways
- Photrexa Viscous holds a dominant position in the keratoconus cross-linking space, with steady revenue growth driven by increased procedural adoption.
- The market is constrained by reimbursement and awareness but shows robust future expansion potential, especially via international markets.
- Pricing is competitive within combined procedural costs, with margins supported by high device and drug demand.
- Innovations, such as new formulations or combination therapies, could influence market share dynamics.
FAQs
-
What are the primary factors affecting Photrexa Viscous’s market growth?
Adoption rates, reimbursement policies, regulatory approvals, and clinician awareness mostly influence growth.
-
How does Photrexa Viscous compare to off-label alternatives?
FDA-approved status markedly favors Photrexa Viscous over unapproved off-label agents, which lack regulatory validation.
-
What is the international market potential?
Many countries have growing ophthalmic procedures with regulatory pathways similar to the U.S., offering expansion opportunities.
-
Are there ongoing clinical trials altering the drug's prospects?
Yes. Trials evaluating expanded indications or combinations could increase utilization.
-
What is the competitive threat from new technologies?
Innovations such as alternative cross-linking techniques or devices could challenge Photrexa Viscous’s market dominance.
Sources
[1] Fortune Business Insights, "Ophthalmic Care Market Size," 2022.
[2] Rabinowitz, Y. S., et al. "Epidemiology of Keratoconus," Progress in Retinal and Eye Research, 2015.
